Clinical Scorecard: Influence of Sociodemographic Factors on the Clinical Features of High-Grade Gliomas: A Retrospective Study Across Multiple Institutions

At a Glance

Key Highlights

• HGG incidence varies by race and ethnicity, with European Americans having higher rates and older age at diagnosis.
• Clinical presentation differs by sociodemographic factors: White patients more often present with cognitive deficits; Black and Hispanic patients more frequently present with severe symptoms like syncope and seizures.
• White patients show less midline shift and mass effect on imaging compared to Black and Hispanic patients, indicating potential differences in tumor progression or detection.

Guideline-Based Recommendations

Diagnosis

• Confirm HGG diagnosis via pathology and WHO grading (III or IV).
• Determine IDH1 mutation status using immunohistochemical staining to inform prognosis.
• Consider sociodemographic factors and symptom presentation patterns when evaluating patients.

Management

• Tailor treatment plans acknowledging differences in clinical presentation and potential disparities in access to care.
• Monitor for generalized symptoms (headache, nausea, seizures) and focal neurological deficits based on tumor location and growth.

Monitoring & Follow-up

• Use Karnofsky Performance Status (KPS) to assess functional status across diverse patient populations.
• Monitor imaging for midline shift and mass effect, especially in Black and Hispanic patients who may present with more severe imaging findings.

Risks

• Recognize that HGG carries poor prognosis with median survival 12–72 months depending on grade.
• Be aware of disparities in symptom severity and presentation that may impact timely diagnosis and outcomes.

Patient & Prescribing Data

317 adult patients with pathology-confirmed HGG from diverse racial and ethnic backgrounds treated at three US tertiary centers.

Sociodemographic factors influence clinical presentation and may affect treatment timing and outcomes; further research needed to optimize personalized care.

Clinical Best Practices

• Incorporate sociodemographic data including race, ethnicity, and social vulnerability indices into clinical assessment.
• Recognize and address potential disparities in symptom recognition and healthcare access.
• Use multidisciplinary approaches to manage neurological symptoms and functional impairments.
• Apply standardized performance scales like KPS to monitor patient status longitudinally.

References

• Primary brain malignancies and glioma classification
• WHO classification of high-grade gliomas
• IDH genotype and glioma prognosis
• Glioma incidence and sociodemographic disparities
• Clinical presentation of gliomas
• Survival rates and outcomes in high-grade gliomas
• Social Vulnerability Index (SVI) methodology